- 2024,04,27
On the evening of August 23rd, Zhejiang Chengyi Pharmaceutical Co., Ltd. released its semi annual performance report for 2023. The report showed that in the first half of this year, the company's operating revenue was approximately 321 million yuan, an increase of 0.85% year-on-year; The net profit attributable to the shareholders of the listed company was approximately 90.6 million yuan, an increase of 39.48% year-on-year; The basic earnings per share were 0.28 yuan, an increase of 40% year-on-year. The report shows that since the beginning of this year, the company's main business has developed steadily, and new products such as ultra-high purity fish oil EPA soft capsules have been vigorously promoted online and offline, with the potential to increase sales. The "two strong and one large" strategy continues to be promoted.
From January to June this year, the pharmaceutical manufacturing industry accounted for 99.84% of the company's operating revenue, and its main business has been steadily developing, continuously increasing its performance. In order to further promote the strategy of "two strong and one big" (to strengthen the ammonia sugar industry and fish oil industry, and to expand the health industry), the company launched four specifications of ultra-high purity EPA fish oil health food "Yuzhongyou R", "Yushengkang R", "Sankang R", and "Wasepar R" soft capsules at the end of last year, which have been channeled online and offline through e-commerce platforms such as JD, Tiktok, Tmall, and WeChat Mall, We have gained a good impression and sales volume among consumers across the country. In the second half of the year, we will increase the promotion and promotion of big health products through cooperation with CCTV's "National Archives" program and other programs, striving to obtain new sales. Based on the benign growth of performance and the potential for high-quality development of the company, the Cui Wenliang team of Huaxi Securities once again gave a "buy" rating to the company's stock on March 7 of this year.
Next, the company's marketing center will continue to deeply cultivate the target markets of each product line, explore the new potential of the product line, continuously expand the breadth and depth of the marketing network, select regional distributors and promoters at all levels, and do a good job in maintaining and managing distributors and promoters. Continuously provide in-depth and detailed market services and brand promotion for flagship products such as glucosamine hydrochloride capsules, promote the "two strong and one large" strategy, and promote the high-quality development of the company. Wu Fengxu
Article source: Dazhong Securities Network